A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine.
10.4046/trd.2012.72.2.207
- Author:
Youn Jung PARK
1
;
Keun Suk YANG
;
Hong Soon JUNG
;
Hee Chul NAM
;
Seung Hye JUNG
;
Boo Gyoung KIM
;
Ka Young KIM
;
Jung Ho KIM
;
Young Ok KIM
;
Yu Seon YUN
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. junpearl19@naver.com
- Publication Type:Case Report
- Keywords:
Hemolytic-Uremic Syndrome;
Gemcitabine;
Lung Neoplasms
- MeSH:
Acute Kidney Injury;
Aged;
Anemia, Hemolytic;
Bleomycin;
Carcinoma, Non-Small-Cell Lung;
Cisplatin;
Deoxycytidine;
Hemolytic-Uremic Syndrome;
Humans;
Lung;
Lung Neoplasms;
Mitomycin;
Plasma Exchange;
Renal Dialysis;
Thrombocytopenia
- From:Tuberculosis and Respiratory Diseases
2012;72(2):207-211
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.
